Varying nicotine patch dose and type of smoking cessation counseling

D. E. Jorenby, S. S. Smith, M. C. Fiore, R. D. Hurt, K. P. Offord, I. T. Croghan, J. T. Hays, S. F. Lewis and T. B. Baker
Center for Tobacco Research and Intervention, University of Wisconsin-Madison, USA.

OBJECTIVE--To compare the efficacy and safety of 22-mg and 44-mg doses of transdermal nicotine therapy when it is paired with minimal, individual, or group counseling to improve smoking cessation rates. DESIGN--An 8-week clinical trial (4 weeks double-blind followed by 4 weeks open label) using random assignment of participants to both dose (22 or 44 mg) and counseling (minimal, individual, or group) conditions. PARTICIPANTS--Daily cigarette smokers (> or = 15 cigarettes per day for at least 1 year) who volunteered to participate in a study of smoking cessation treatment. A total of 504 participants were enrolled at two sites. INTERVENTION--Four weeks of 22- or 44-mg transdermal nicotine therapy followed by 4 weeks of dosage reduction (2 weeks of 22 mg followed by 2 weeks of 11 mg). Counseling consisted of a self-help pamphlet (minimal); a self-help pamphlet, a brief physician motivational message, and three brief (< 15 minutes) follow-up visits with a nurse (individual); or the pamphlet, the motivational message, and eight weekly 1-hour group smoking cessation counseling visits (group). All participants returned weekly to turn in questionnaires and for assessment of their smoking status. MAIN OUTCOME MEASURES--Abstinence from smoking was based on self-report, confirmed by an expired carbon monoxide concentration lower than 10 ppm. Withdrawal severity was assessed by means of an eight-item self-report questionnaire completed daily. RESULTS--Smoking cessation rates for the two nicotine patch doses and three levels of counseling did not differ significantly at either 8 weeks or 26 weeks following the quit date. Among those receiving minimal contact, the 44-mg dose produced greater abstinence at 4 weeks than did the 22-mg dose (68% vs 45%; P < .01). Participants receiving minimal-contact adjuvant treatment were less likely to be abstinent at the end of 4 weeks than those receiving individual or group counseling (56% vs 67%; P < .05). The 44-mg dose decreased desire to smoke more than the 22-mg dose, but this effect was not related to success in quitting smoking. Transdermal nicotine therapy at doses of 44 mg produced a significantly greater frequency of nausea (28%), vomiting (10%), and erythema with edema at the patch site (30%) than did a 22-mg dose (10%, 2%, and 13%, respectively; P < .01 for each adverse effect). Three serious adverse events occurred during use of the 44-mg patch dose. CONCLUSIONS--There does not appear to be any general, sustained benefit of initiating transdermal nicotine therapy with a 44-mg patch dose or of providing intense adjuvant smoking cessation treatment. The two doses and all adjuvant treatments produced equivalent effects at the 26-week follow-up, and the higher patch dose produced more adverse effects. Higher-dose (44-mg) nicotine replacement does not appear to be indicated for general clinical populations, although it may provide short-term benefit to some smokers attempting to quit with minimal adjuvant treatment.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neural Substrates of Abstinence-Induced Cigarette Cravings in Chronic Smokers
Wang et al.
J. Neurosci. 2007;27:14035-14040.
ABSTRACT | FULL TEXT  

Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review
Leeman et al.
Alcohol Alcohol 2007;42:196-206.
ABSTRACT | FULL TEXT  

Reduction in cortisol after smoking cessation among users of nicotine patches.
Ussher et al.
Psychosom. Med. 2006;68:299-306.
ABSTRACT | FULL TEXT  

Self-Reported Smoking Status and Exhaled Carbon Monoxide: Results From Two Population-Based Epidemiologic Studies in the North of England
Pearce et al.
Chest 2005;128:1233-1238.
ABSTRACT | FULL TEXT  

Pharmacotherapy for Nicotine Dependence
Henningfield et al.
CA Cancer J Clin 2005;55:281-299.
ABSTRACT | FULL TEXT  

Pharmacotherapy and Pharmacogenetics of Nicotine Dependence
Berrettini and Lerman
Am. J. Psychiatry 2005;162:1441-1451.
ABSTRACT | FULL TEXT  

Treating Tobacco Dependence: State of the Science and New Directions
Lerman et al.
JCO 2005;23:311-323.
ABSTRACT | FULL TEXT  

Nicotine replacement therapy in smoking cessation
Campbell
Thorax 2003;58:464-465.
FULL TEXT  

Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking
Hurt et al.
JCO 2003;21:914-920.
ABSTRACT | FULL TEXT  

Increase in common cold symptoms and mouth ulcers following smoking cessation
Ussher et al.
Tobacco Control 2003;12:86-88.
ABSTRACT | FULL TEXT  

Bupropion for Smoking Cessation : Predictors of Successful Outcome
Dale et al.
Chest 2001;119:1357-1364.
ABSTRACT | FULL TEXT  

New Developments in Smoking Cessation
Prochazka
Chest 2000;117:169S-175S.
ABSTRACT | FULL TEXT  

Breath Carbon Monoxide as an Indication of Smoking Habit
Middleton and Morice
Chest 2000;117:758-763.
ABSTRACT | FULL TEXT  

Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up • Commentary: Progress on nicotine replacement therapy for smokers
Blondal et al.
BMJ 1999;318:285-289.
ABSTRACT | FULL TEXT  

Suppression of Nicotine Intake During Ad Libitum Cigarette Smoking by High-Dose Transdermal Nicotine
Benowitz et al.
J. Pharmacol. Exp. Ther. 1998;287:958-962.
ABSTRACT | FULL TEXT  

Usage patterns of transdermal nicotine when purchased as a non-prescription medicine from pharmacies
Shaw et al.
Tobacco Control 1998;7:161-167.
ABSTRACT | FULL TEXT  

Atherosclerosis and Risk Factor Modification: Does It Really Make a Difference?
Corson et al.
PERSPECT VASC SURG ENDOVASC THER 1996;9:75-94.
 

Are High-Dose Nicotine Patches Better?
JWatch Psychiatry 1996;1996:19-19.
FULL TEXT  

HIGH-DOSE NICOTINE PATCHES: BETTER THAN STANDARD- DOSE?
JWatch General 1995;1995:4-4.
FULL TEXT